Table 4 Factors Associated with Poor Progression-Free Survival.

From: Predictive and Prognostic Value of 18F-fluorodeoxyglucose Uptake Combined with Thymidylate Synthase Expression in Patients with Advanced Non-Small Cell Lung Cancer

 

Univariate

Multivariate

HR

95% CI

P-value

HR

95% CI

P-value

Male (vs. female)

1.53

1.16–2.01

0.003

1.51

0.95–2.39

0.080

Ever smoked (vs. never smoker)

1.35

1.03–1.77

0.030

0.92

0.57–1.46

0.708

High TLG

1.50

1.10–2.03

0.010

1.39

1.01–1.93

0.043

Age ≥65 years (vs. <65 years)

1.35

1.02–1.80

0.037

1.27

0.91–1.78

0.175

TS-positive (vs. TS-negative)

1.49

1.12–1.96

0.005

1.25

0.90–1.73

0.181

AP group (vs. GP group)

0.71

0.54–0.94

0.015

0.68

0.49–0.93

0.017

EGFR wild-type (vs. mutation)

1.24

0.93–1.64

0.148

   

ALK rearrangement

0.83

0.47–1.45

0.504

   
  1. HR, hazard ratio; CI, confidence interval; TLG, total lesion glycolysis; TS, thymidylate synthase; AP, pemetrexed/cisplatin-treated; GP, gemcitabine/cisplatin-treated; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase.
Back to article page